Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine

Clinical Cancer Research

Volumn 15, Issue 22, 2009, Pages 7029-7035

  Faries, Mark B ^a   Hsueh, Eddy C ^a   Ye, Xing ^a   Hoban, Mary ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CANVAXIN; IMMUNOGLOBULIN M; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TA90 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BASOPHIL; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG DOSE REDUCTION; EOSINOPHIL; FATIGUE; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL; MONOCYTE; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; AGED; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEUKOCYTES; MALE; MELANOMA; MIDDLE AGED; PILOT PROJECTS; SKIN NEOPLASMS;

EID: 72549086588     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1540     Document Type: Article

References (35)

1. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1998;90:3539-3543
2. Mach N, Gillessen S, Wilson SB, et al. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000;60:3239-3246 (Pubitemid 30407923)
3. Gillessen S, Naumov YN, Nieuwenhuis EE, et al. CD1d-restricted T cells regulate dendritic cel l function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc Natl Acad Sci U S A 2003;100:8874-8879
4. Fischer HG, Frosch S, Reske K, et al. Granulocyte-macrophage colony-stimulating factor activates macrophages derived frombone marrow-cultures to synthesis of MHCclass II molecules and to augmented antigen presentation function. J Immunol 1988;141:3882-3888 (Pubitemid 18279954)
5. Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000;18:1614-1621
6. Hsueh E, Essner R, Foshag L, et al. Active specific immunotherapy of melanoma with a polyvalent vaccine and recombinant human GM-CSF: an immunogenicity study. Proc Am Soc Clin Oncol 2003;22:176.
7. Morton D, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin 1996;46:225-244
8. Morton D, Foshag L, Hoon D, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-482.
9. Gupta R, Morton D. Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated-antigen-specific immune complexes in cancer. J Clin Lab Anal 1992;6:329-336.
10. Euhus DM, Gupta RK, Morton DL. Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother 1989;29:247-254 (Pubitemid 19166456)
11. Hsueh E, Gupta R, Qi K, et al. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998;16:2913-2920
12. Yagci M, Acar K, Sucak GT, et al. Hepatitis B virus vaccine in lymphoproliferative disorders: a prospective randomized study evaluating the efficacy of granulocyte-macrophage colony stimulating factor as a vaccine adjuvant. Eur J Haematol 2007;79:292-296
13. Anandh U, Bastani B, Ballal S. Granulocyte-macrophage colony-stimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients. Am J Nephrol 2000;20:53-56 (Pubitemid 30047871)
14. Celis E. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. Cancer 2007;110:203-214
15. Marshall JL, Gulley JL, Arlen PM, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005;23:720-731
16. Slingluff CL, Jr., Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21:4016-4026
17. Hamid O, Solomon JC, Scotland R, et al. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res 2007;13:215-222 (Pubitemid 46121871)
18. Mattei S, Colombo MP, Melani C, et al. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 1994;56:853-857
19. Gasson JC. Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 1991;77:1131-1145
20. Baldwin GC, Golde DW, Widhopf GF, et al. Identification and characterization of a low-affinity granulocyte-macrophage colony-stimulating factor receptor on primary and cultured human melanoma cells. Blood 1991;78:609-615
21. Serafini P, De Santo C, Marigo I, et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004;53:64-72. (Pubitemid 38161211)
22. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006;55:237-245 (Pubitemid 41683212)
23. Larrivee B, Pollet I, Karsan A. Activation of vascular endothelial growth factor receptor-2 in bone marrow leads to accumulation of myeloid cells: role of granulocyte-macrophage colony-stimulating factor. J Immunol 2005;175:3015-3024
24. Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009;58:49-59.
25. Serafini P, Carbley R, Noonan KA, et al. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004;64:6337-6343 (Pubitemid 39129439)
26. Jager E, Ringhoffer M, Dienes HP, et al. Granulocyte-macrophage-colony- stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 1996;67:54-62. (Pubitemid 26236069)
27. Scheibenbogen C, Schmittel A, Keilholz U, et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother 2000;23:275-281 (Pubitemid 30165177)
28. Ullenhag GJ, Frodin JE, Mosolits S, et al. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony-stimulating factor induced a tumor-specific cellular immune response. Clin Cancer Res 2003;9:2447-2456
29. Parmiani G, Castelli C, Pilla L, et al. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007;18:226-232 (Pubitemid 46323086)
30. Dillman R, Weimann M, Nayak S, et al. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the Cancer Biotherapy Research Group. J Immunother 2003;26:367-373
31. Weber J, Sondak VK, Scotland R, et al. Granulocyte-macrophage-colony- stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 2003;97:186-200. (Pubitemid 36033878)
32. Simmons SJ, Tjoa BA, Rogers M, et al. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 1999;39:291-297 (Pubitemid 29244504)
33. Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002;20:4169-4180
34. Hewitt RG, Morse GD, Lawrence WD, et al. Pharmacokinetics and pharmacodynamics of granulocyte-macrophage colony-stimulating factor and zidovudine in patients with AIDS and severe AIDS-related complex. Antimicrob Agents Chemother 1993;37:512-522
35. Hsueh E, Essner R, Foshag L, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002;20:4549-4554 (Pubitemid 35402957)